ION859 (formerly IONIS-BIIB7Rx), also known as BIIB094, is an investigational antisense medicine designed to inhibit the production of the leucine-rich repeat kinase 2 (LRRK2) protein as a potential therapy for Parkinson’s disease (PD). The most common PD-associated genetic mutations are found in the LRRK2 gene. It is believed that increased LRRK2 protein and function could be one of the key drivers for developing PD.

About Parkinson’s Disease (PD)

PD is a progressive neurodegenerative disease characterized by loss of dopamine-producing neurons in the part of the brain that controls movement. Patients with PD can experience tremors, loss of balance and coordination, stiffness, slowing of movement, changes in speech and eventually in most cases significant cognitive decline. PD is associated with a shortened lifespan. There are treatments that can relieve symptoms for a limited period of time, but there are no approved treatments that modify the course of the disease.

Safety and efficacy have not been evaluated by any regulatory authorities for the indication described.

You are now leaving to visit